• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Artiva Biotherapeutics Inc.

    7/22/24 5:30:07 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email
    S-8 1 d874189ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on July 22, 2024

    Registration No. 333-  

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Artiva Biotherapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-3614316

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    5505 Morehouse Drive, Suite 100

    San Diego, CA

      92121
    (Address of Principal Executive Offices)   (Zip Code)

    Artiva Biotherapeutics, Inc. 2020 Equity Incentive Plan

    Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan

    Artiva Biotherapeutics, Inc. 2024 Employee Stock Purchase Plan

    (Full titles of the plans)

    Fred Aslan, M.D.

    President and Chief Executive Officer

    Artiva Biotherapeutics, Inc.

    5505 Morehouse Drive, Suite 100

    San Diego, CA 92121

    (858) 267-4467

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Carlos Ramirez

    Charles S. Kim

    Cooley LLP

    10265 Science Center Drive

    San Diego, CA 92121

    (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”) and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

     

    (a)

    The Registrant’s prospectus filed on July  22, 2024 pursuant to Rule 424(b) of the Securities Act relating to the Registration Statement on Form S-1, as amended (File No. 333-280568), initially filed with the Commission on June 28, 2024, which contains audited financial statements for the Registrant’s latest fiscal year for which such statements have been filed; and

     

    (b)

    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed on July 16, 2024 (File No. 001-42179) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    Item 4.

    Description of Securities.

    Not applicable.

     

    Item 5.

    Interests of Named Experts and Counsel.

    Not applicable.

     

    Item 6.

    Indemnification of Directors and Officers.

    As permitted by Sections 102 and 145 of the Delaware General Corporation Law, the Registrant has adopted provisions in its amended and restated certificate of incorporation and amended and restated bylaws that limit or eliminate the personal liability of its directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:


      •  

    any breach of the director’s duty of loyalty to the Registrant or its stockholders;

     

      •  

    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

      •  

    any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or

     

      •  

    any transaction from which the director derived an improper personal benefit.

    These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. The Registrant’s amended and restated certificate of incorporation also authorizes it to indemnify its officers, directors and other agents to the fullest extent permitted under Delaware law.

    As permitted by Section 145 of the Delaware General Corporation Law, the Registrant’s amended and restated bylaws provide that:

     

      •  

    the Registrant may indemnify its directors, officers, employees and other agents to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;

     

      •  

    the Registrant may advance expenses to its directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

     

      •  

    the rights provided in the Registrant’s bylaws are not exclusive.

    The Registrant’s amended and restated certificate of incorporation and its bylaws, as amended, provide for the indemnification provisions described above. The Registrant has entered into, and intends to continue to enter into, separate indemnification agreements with its directors and officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require the Registrant, among other things, to indemnify its officers and directors against certain liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require the Registrant to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.

    The Registrant has purchased and currently intends to maintain insurance on behalf of each and every person who is one of its directors or officers, within the limits and subject to the terms and conditions thereof, against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

     

    Item 7.

    Exemption from Registration Claimed.

    Not applicable.

     

    Item 8.

    Exhibits.

    The exhibits to this Registration Statement are listed below:


    Exhibit
    Number
      

    Description

    4.1    Amended and Restated Certificate of Incorporation, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-42179, filed with the Commission on July 22, 2024).
    4.2    Amended and Restated Bylaws, as currently in effect (incorporated herein by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).
    4.3    Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).
    4.4    Amended and Restated Investors’ Rights Agreement, dated February 22, 2021, by and among the Registrant and certain of its stockholders (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).
    5.1*    Opinion of Cooley LLP.
    23.1*    Consent of Independent Registered Public Accounting Firm.
    23.2*    Consent of Cooley LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on signature page).
    99.1    2020 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).
    99.2    Form of Stock Option Grant Notice, Stock Option Grant Notice with Acceleration of Vesting, Option Agreement and Notice of Exercise under the 2020 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commissionon June 28, 2024).  
    99.3*    2024 Equity Incentive Plan.
    99.4    Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).
    99.5    Form of Restricted Stock Unit Grant Notice and Award Agreement under the 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).
    99.6*    2024 Employee Stock Purchase Plan.
    107*    Filing Fee Disclosure and Payment Methods.

     

    *

    Filed herewith.

     

    Item 9.

    Undertakings.

     

    (a)

    The undersigned Registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;


      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on July 22, 2024.

     

    ARTIVA BIOTHERAPEUTICS, INC.
    By:  

    /s/ Fred Aslan, M.D.

      Fred Aslan, M.D.
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Fred Aslan, M.D. and Neha Krishnamohan and each of them, as his or her true and lawful attorneys-in-fact and agents, and each of them, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Fred Aslan, M.D.

    Fred Aslan, M.D.

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      July 22, 2024

    /s/ Neha Krishnamohan

    Neha Krishnamohan

      

    Chief Financial Officer and EVP, Corporate Development

    (Principal Financial and Accounting Officer)

      July 22, 2024

    /s/ Brian Daniels, M.D.

    Brian Daniels, M.D.

       Chairperson of the Board of Directors   July 22, 2024

    /s/ Laura Bessen, M.D.

    Laura Bessen, M.D.

       Director   July 22, 2024

    /s/ Elizabeth Hougen

       Director   July 22, 2024
    Elizabeth Hougen


    /s/ Yong Jun-Huh

    Yong-Jun Huh

       Director   July 22, 2024

    /s/ Diego Miralles, M.D.

    Diego Miralles, M.D.

       Director   July 22, 2024

    /s/ Laura Stoppel, Ph.D.

    Laura Stoppel, Ph.D.

       Director   July 22, 2024
    Get the next $ARTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

    6/11/25 7:52:47 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

    12/30/24 7:13:58 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

    Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

    8/13/24 7:24:03 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

    SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL). The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings: Post

    1/21/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

    – 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials     COVENTRY, England, Jan. 8, 2026 /PRNewswire/ -- NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Thomas J. Farrell as Chief Executive Officer and Director. Tom succeeds company founder Joe Healey, who will remain involved in the company, ensuring continuity and o

    1/8/26 3:30:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

    32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with no specialized oncology oversight, demonstrating the feasibility of administering this regimen outside the hospital setting No cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) Consistent and complete B-cell depletion was observed in all patients with autoimmune disease treated with AlloNK + mAb by Day 13 of treatment, consistent with the experience for AlloNK + mAb in B-cell driven lymphoma Ar

    11/12/25 7:20:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Aslan Fred sold $19,122 worth of shares (3,187 units at $6.00), decreasing direct ownership by 0.26% to 1,209,948 units (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    12/15/25 9:19:28 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, Research and Development Raymon Heather was granted 67,253 shares, increasing direct ownership by 170% to 106,844 units (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    12/12/25 7:21:14 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Tech Operations Officer Horan Christopher was granted 107,156 shares, increasing direct ownership by 137% to 185,339 units (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    12/12/25 7:20:38 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    SEC Filings

    View All

    SEC Form 8-K filed by Artiva Biotherapeutics Inc.

    8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    12/12/25 5:23:56 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    11/12/25 7:22:26 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Artiva Biotherapeutics Inc.

    10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    11/12/25 7:08:13 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/24/24 4:27:11 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/24/24 4:15:09 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/22/24 8:26:49 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Leadership Updates

    Live Leadership Updates

    View All

    Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

    – 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials     COVENTRY, England, Jan. 8, 2026 /PRNewswire/ -- NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Thomas J. Farrell as Chief Executive Officer and Director. Tom succeeds company founder Joe Healey, who will remain involved in the company, ensuring continuity and o

    1/8/26 3:30:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

    IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

    5/8/25 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

    SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

    4/8/25 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

    SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    11/14/24 4:56:18 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

    SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    9/3/24 4:18:05 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

    SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    8/1/24 7:00:07 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care